A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
Status:
Recruiting
Trial end date:
2024-02-12
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to
placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult
participants with new-onset or relapsing giant cell arteritis (GCA).